Company: INTS
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001567264-25-000039
Chunk: 24

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 24
---
 begin to expire in September 2025. Options that were granted to employees and consultants have vesting periods that vary by award to recipient and range from immediate vesting to a period of up to 4 years.As of March 31, 2025, total unrecognized compensation cost related to options was approximately $4.0 million and is expected to be recognized over the remaining weighted average service period of 2.5 years.

9

WarrantsThe following table summarizes the range of assumptions used to estimate the fair value of warrants issued using the Black-Scholes-Merton option pricing model:Three Months Ended March 31,20252024Stock pricen/a$5.19Exercise pricen/a$5.19Expected volatilityn/a97.06%Risk free interest ratesn/a4.12%Expected term (years)n/a6.25The Company did not issue warrants for the three months ended March 31, 2025. For the three months ended March 31, 2024, a dividend yield of 0% was used because the Company has not historically paid and does not intend to pay a dividend on common stock in the foreseeable future. The expected stock price volatility assumption was estimated based on the historical volatilities for industry peers, as the Company had no active market for its stock prior to the IPO and limited history for issuance price of its stock. The risk-free rate assumption is determined using the yield currently available on U.S. Treasury zero coupon issues with a remaining term commensurate with the expected term of the award. The expected term of the warrant represents the period the warrants are expected to be outstanding.The following table summarizes the activity for warrants for the three months ended March 31, 2025:WarrantsWeighted-Average Exercise PriceWeighted Average Remaining Contractual Term (in years)Aggregate Intrinsic Value (in thousands)Outstanding at December 31, 20242,041,563 $4.32 4.7$— Issued— $— Exercised— $— Forfeited and cancelled— $— Outstanding at March 31, 20252,041,563 $4.32 4.4$— Exercisable at March 31, 2025753,450 $6.50 3.2$— All warrants outstanding are exercisable for purchase of common stock. As of March 31, 2025, total unrecognized compensation cost related to warrants